Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The state-of-the-art facility is expected to be commissioned over the next three years
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The audit was completed with zero critical and zero major observations
Subscribe To Our Newsletter & Stay Updated
